Longeveron's experimental stem cell therapy for a pediatric heart disease failed its phase 2b trial, missing the main goal of the study. The company, which had limited cash reserves, now says it will examine every possible path forward, including a sale, merger, or other restructuring.
In the wake of the setback, Longeveron plans to reduce spending and explore "all options" for the business, according to the company's announcement. The trial's failure is a significant blow to the therapy's development, and the financial strain is likely to accelerate the need for a strategic decision.
No other sources were provided, so this report relies solely on the Fierce Biotech article. The company has not yet disclosed detailed efficacy or safety data from the trial, and the specific timeline for its strategic review remains unclear.